Skip to main content
Fig. 3 | BMC Cancer

Fig. 3

From: Involvement of mutant and wild-type CYSLTR2 in the development and progression of uveal nevi and melanoma

Fig. 3

Allelic balance at the CYSLTR2 locus in CYSLTR2 mutant and wild-type uveal melanomas. a Comparison of DNA and RNA levels of mutant versus wild-type CYSLTR2 alleles in two mutant primary uveal melanomas from our cohort, showing increased relative abundance of the mutant allele at RNA level in both tumours. b Three mutant primary uveal melanomas from the TCGA cohort, of which two show an allelic imbalance towards the mutant allele at RNA level. c Mutant metastatic uveal melanoma from the CheckMate-038 clinical trial showing skewed RNA expression towards the mutant allele. d Balanced biallelic expression of CYSLTR2 in three copy number stable wild-type primary uveal melanomas from the TCGA cohort. e A wild-type primary uveal melanoma from the TCGA cohort with an allelic imbalance involving the CYSLTR2 locus at chromosome 13q presents with proportional expression levels

Back to article page